Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967711 | 0.84 | ATM (0.69) | ALDH1A1HPGDLMNAPOLBHTT | |
| Hydrochloric Acid SCHEMBL21391938 | 0.82 | ATM (0.67) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL4220065 | 0.81 | ALDH1A1 (0.69) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL3027076 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL601912 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL2644442 | 0.81 | ALDH1A1 (1.00) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL3467136 | 0.81 | ALDH1A1 (0.63) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL21384242 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDLMNAPOLBHTT | |
| SCHEMBL15884611 | 0.79 | ALDH1A1 (0.70) | ALDH1A1HPGDLMNAPOLBHTT | |
| Hydrogen Sulfide SCHEMBL28084028 | 0.79 | ALDH1A1 (0.96) | ALDH1A1HPGDLMNAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| CN-102365273-A | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | SANOFI AVENTIS | 2012-02-29 | — | — | CN | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| EP-2147473-A1 | HYBRID FLUORESCENT/PHOSPHORESCENT OLEDS | EASTMAN KODAK COMPANY (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008143791-A1 | HYBRID FLUORESCENT/PHOSPHORESCENT OLEDS | EASTMAN KODAK COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | CNKSR1, NOX5, NOX1 | ALDH1A1 3896/4885HPGD 1147/4885LMNA 3000/4885 |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ALDH1A1 126/4885HPGD 28/4885LMNA 4261/4885 |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | ALDH1A1 458/4885HPGD 203/4885LMNA 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.